1Holmes CB, Losina E, Walensky RP, et al. Review of human immunodeficiency virus type 1-related opportunistic infections in Sub-Saharan Africa[J]. Clin Infect Dis, 2003,36 ( 5 ) : 652- 662.
2Brandt ME, Pfaller MA, Hajjeh RA, et al. Trends in anti-fungal drug susceptibility of Cryptoeoccus neoformans isolates in the United States:1992 to 1994 and 1996 to 1998[J]. Antimi-corb Agents Chemother,2001,45(11):3 065-3 069.
5Larsen RA,Pappas PG, Perfect J.et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticrypto- coccal antibody 18B? in subjects with treated cryptococeal men- ingitis[J].Antimicrob Agents Chemother, 2005,49(3):952- 958.
8Galanis E, Macdougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis, 2010, 16:251-257.
9Noverr MC, Wilhamson PR, Fajardo RS, Huffnagle GB. CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect Immun, 2004, 72:1693-1699.
10Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol, 2004, 164:1761-1771.
